logo

Last Update

This profile was last updated on 3/17/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong John Schembri?

John Schembri

Vice President Finance and Administration

Global Blood Therapeutics, Inc.

HQ Phone:  (650) 741-7700

Email: j***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Global Blood Therapeutics, Inc.

400 East Jamie Court Suite 101

South San Francisco, California, 94080

United States

Company Description

Global Blood Therapeutics is the third company in the sickle cell disease field to go public recently. Bluebird Bio Inc., which went public in 2013, is studying a potential gene therapy for the condition, while Bellicum Pharmaceuticals Inc., which had its IPO ...more

Find other employees at this company (182)

Background Information

Employment History

Executive Vice President and Chief Financial Officer

TriAct Therapeutics, Inc.


Chief Financial Officer

Biotechnology Council


Chief Financial Officer

BiPar Sciences , Inc.


Chief Financial Officer

Stempar Sciences, Inc.


Financial Management Positions

The Clorox Company


Web References(27 Total References)


Readying a young life sciences company for its first audit - RoseRyan

"Our senior player from RoseRyan was phenomenal and got us ready for our first audit," says John Schembri, VP of finance at Global Blood Therapeutics.
So much so that they expanded the guru's duties, having her help with accounting for equity compensation plans. When she needed examples or feedback, the guru leaned on the collective intelligence of her RoseRyan colleagues. The consultant "fit in very well with our team, and she gained their trust quickly," Schembri says. Reaffirming this trust, the company is bringing back RoseRyan for their next big project.


Accolades & awards - RoseRyan

John Schembri
VP of Finance, Global Blood Therapeutics


Management Team | Investors | Global Blood Therapeutics

John Schembri
Vice President, Finance and Administration John Schembri joined Global Blood Therapeutics as vice president, finance and administration in January 2014. Mr. Schembri has more than 25 years of experience as a finance executive in the biotechnology industry and previously served as chief financial officer of BiPar Sciences, which was acquired by Sanofi-Aventis for $500 million. Prior to that Mr. Schembri led the finance team at Sirna Therapeutics, which was acquired by Merck & Co. for $1.1 billion. He also served a key role in the $2 billion sale and integration of COR Therapeutics to Millennium Pharmaceuticals in 2001.


Senior Management | Global Blood Therapeutics

John Schembri
Vice President, Finance and Administration John Schembri joined Global Blood Therapeutics as vice president, finance and administration in January 2014. Mr. Schembri has more than 25 years of experience as a finance executive in the biotechnology industry and previously served as chief financial officer of BiPar Sciences, which was acquired by Sanofi-Aventis for $500 million. Prior to that Mr. Schembri led the finance team at Sirna Therapeutics, which was acquired by Merck & Co. for $1.1 billion. He also served a key role in the $2 billion sale and integration of COR Therapeutics to Millennium Pharmaceuticals in 2001.


http://www.sec.gov/Archives/edgar/data/1629137/0001629137-16-000038.txt

John Schembri
John Schembri has served as our Vice President, Finance and Administration since January 2014. Prior to joining us, since June 2011, Mr. Schembri served as vice president and chief financial officer at StemPar Sciences, Inc. From July 2009 to May 2011, he was a consulting chief financial officer to early-stage companies. Prior to that, Mr. Schembri served as chief financial officer of BiPar Sciences, Inc., from January 2007 until it was acquired by sanofi-aventis S.A. in 2009. Prior to joining BiPar Sciences, Mr. Schembri led the finance team at Sirna Therapeutics, Inc., a biotechnology company, from January 2006 until it was acquired by Merck & Co., Inc. in December 2006. He also served a key role in the $2 billion sale and integration of COR Therapeutics Inc., a biopharmaceutical company, to Millennium Pharmaceuticals, Inc. in 2001. Mr. Schembri holds a B.S. in business administration from California State Polytechnic University, San Luis Obispo.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory